… I extend congratulations to László Kürti and Barbara Czakó for a truly fine accomplishment
and a massive amount of work that made it possible. The scholarship and care that they …

Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued
opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic …

Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on
glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are …

Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s
disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant …

Despite being crucial for energy generation in most forms of life, few if any microbial antibiotics
specifically inhibit glycolysis. To develop a specific inhibitor of the glycolytic enzyme …

These findings highlight the discovery of IACS-13909 as a potent, selective inhibitor of
SHP2 with drug-like properties, and targeting SHP2 may serve as a therapeutic strategy to …

Molecules and Medicine provides, for the first time ever, a completely integrated look at
chemistry, biology, drug discovery, and medicine. It delves into the discovery, application, and …

Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have
previously identified a subset of cancers harbouring homozygous deletion of the glycolytic …

The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted
therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such …

Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting
step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a …